CSI Market
Sign In | Register

Regenerx Biopharmaceuticals inc (RGRX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RGRX Annual Cash Flow →
The table below presents a historical view of Regenerx Biopharmaceuticals inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2023)
3 Months 		(Dec 31 2022) (Sep 30 2022) (Jun 30 2022) (Mar 31 2022)
Operating Activities
Income-0.39
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.09
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Share Based Compensation To Non Employees-
Fair Value Of Derivative Liabilities Gain Loss Gross-
Amortization Of Operating Lease Right Of Use Assets-
Increase Decrease Of Operating Lease Liabilities-
Increase Decrease In Rights Of Used Assets And Liabilities0.00
Gain On Forgiveness Of Paycheck Protection Program Loan-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.03
Increase (Decrease) in Accrued Liabilities0.10
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.01
Other Working Capital0.00
Other Noncash Expense0.06
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.02
Discontinued operations0.00
Net Cash flow from Operating Activities-0.19
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Private Placement Net Of Offering Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.19
Total Cash Flow-0.19
4 historic quarters locked

Sign in to unlock the full Regenerx Biopharmaceuticals inc cash flow history.

Sign In Create Free Account

About Regenerx Biopharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001410578-23-001223

Figures are derived from filed reports and may be restated. Historical data is subject to revision.